Stockreport

Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics, Inc.  (CLDI) 
PDF Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic immunotherapy utilizing neural [Read more]